Molecular Insights of Cholestasis in MDR2 Knockout Murine Liver Organoids

Irene Blázquez-García,Laura Guerrero,Cristina Cacho-Navas,Nabil Djouder,Jaime Millan,Alberto Paradela,Lorena Carmona-Rodríguez,Fernando J. Corrales,Irene Blázquez-García,Lorena Carmona-Rodríguez

DOI: https://doi.org/10.1021/acs.jproteome.3c00900

2024-03-15

Journal of Proteome Research

Abstract:MDR3 (multidrug resistance 3) deficiency in humans (MDR2 in mice) causes progressive familial intrahepatic cholestasis type 3 (PFIC3). PFIC3 is a lethal disease characterized by an early onset of intrahepatic cholestasis progressing to liver cirrhosis, a preneoplastic condition, putting individuals at risk of hepatocellular carcinoma (HCC). Hepatocyte-like organoids from MDR2-deficient mice (MDR2KO) were used in this work to study the molecular alterations caused by the deficiency of this transporter. Proteomic analysis by mass spectrometry allowed characterization of 279 proteins that were differentially expressed in MDR2KO compared with wild-type organoids. Functional enrichment analysis indicated alterations in three main cellular functions: (1) interaction with the extracellular matrix, (2) remodeling intermediary metabolism, and (3) cell proliferation and differentiation. The affected cellular processes were validated by orthogonal molecular biology techniques. Our results point to molecular mechanisms associated with PFIC3 that may drive the progression to liver cirrhosis and HCC and suggest proteins and cellular processes that could be targeted for the development of early detection strategies for these severe liver diseases.

biochemical research methods

What problem does this paper attempt to address?

The paper primarily explores the molecular mechanisms in hepatocyte-like organoids derived from mice with a defect in the MDR2 gene (MDR3 in humans). The protein encoded by the MDR2 gene plays a crucial role in bile acid secretion, and its defect leads to progressive familial intrahepatic cholestasis type 3 (PFIC3), a severe genetic disorder characterized by early-onset intrahepatic cholestasis, which can eventually lead to cirrhosis and even hepatocellular carcinoma (HCC). The study conducted proteomic analysis using mass spectrometry on liver organoids derived from MDR2 knockout mice (MDR2KO), identifying 279 differentially expressed proteins. Functional enrichment analysis revealed three major affected cellular functions: 1. Interaction between cells and the extracellular matrix (ECM); 2. Remodeling of intermediate metabolism; 3. Regulation of cell proliferation and differentiation. These changes may drive disease progression to cirrhosis and hepatocellular carcinoma and suggest potential early detection strategies or therapeutic targets. Specifically, the study found that liver organoids with MDR2 deficiency exhibited the following characteristics: - Reduced proteins related to interaction with the extracellular matrix (such as mucins and laminins), which may affect cell growth, migration, and interaction with the surrounding environment. - Metabolic reprogramming, including changes in lipid metabolism, such as downregulation of enzymes related to phosphatidylcholine (PC) synthesis and upregulation of enzymes related to cholesterol synthesis. - Changes in the regulation of cell proliferation and differentiation, such as inhibition of the epidermal growth factor receptor (EGFR)/mitogen-activated protein kinase (ERK) signaling pathway. In summary, this study, through detailed molecular biology experiments and technical approaches, delves into the molecular mechanisms of cholestasis caused by MDR2 gene defects, providing important clues for further understanding the pathogenesis of PFIC3 and developing new therapeutic strategies.

Molecular Insights of Cholestasis in MDR2 Knockout Murine Liver Organoids

Molecular basis of progressive familial intrahepatic cholestasis 3. A proteomics study

Loss of apical sodium bile acid transporter alters bile acid circulation and reduces biliary damage in cholangitis

Tolerance of Repeated Toxic Injuries of Murine Livers is Associated with Steatosis and Inflammation

Intestinal dysbiosis augments liver disease progression via NLRP3 in a murine model of primary sclerosing cholangitis

Xenobiotic Nuclear Receptor Signaling Determines Molecular Pathogenesis of Progressive Familial Intrahepatic Cholestasis

Monoacylglycerol Lipase Inhibition Protects From Liver Injury in Mouse Models of Sclerosing Cholangitis

Molecular alterations associated with pathophysiology in liver-specific ZO-1 and ZO-2 knockout mice

Fecal microbiota manipulation prevents dysbiosis and alcohol-induced liver injury in mice

Repeated Toxic Injuries of Murine Liver Are Tolerated Through Microsteatosis and Mild Inflammation

Lack of CC chemokine ligand 2 differentially affects inflammation and fibrosis according to the genetic background in a murine model of steatohepatitis

Cholestatic liver disease results increased production of reactive aldehydes and an atypical periportal hepatic antioxidant response.

Mouse precision-cut liver slices as an ex vivo model to study drug-induced cholestasis

Uncovering key molecules and immune landscape in cholestatic liver injury: implications for pathogenesis and drug therapy

Uncovering a Novel Functional Interaction Between Adult Hepatic Progenitor Cells, Inflammation and EGFR Signaling During Bile Acids-Induced Injury

Oral N-acetylcysteine ameliorates liver fibrosis and enhances regenerative responses in Mdr2 knockout mice

Rapid in vivo evaluation system for cholestasis-related genes in mice with humanized bile acid profiles

Gut Microbial Impact on Colitis and Colitis-Associated Carcinogenesis in a Primary Sclerosing Cholangitis-IBD Model

Novel clinical phenotypes, drug categorization, and outcome prediction in drug-induced cholestasis: Analysis of a database of 432 patients developed by literature review and machine learning support

Absence of the intestinal microbiota exacerbates hepatobiliary disease in a murine model of primary sclerosing cholangitis

Dynamic Alterations of the Gut Microbial Pyrimidine and Purine Metabolism in the Development of Liver Cirrhosis